All In Biotech

NDA 021560 · Novartis

Zortress

Everolimus · Oral · Kinase Inhibitor; mTOR Inhibitor Immunosuppressant

Last checked: Nov 20, 2026Latest source record: Sep 16, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2010

Apr 20, 2010

Approved uses

3

Original approval plus efficacy supplements

Registered trials

881

126 Phase 3, 57 recruiting

FAERS reports

18,496

16,082 serious, 2,839 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: MALIGNANCIES, SERIOUS INFECTIONS, KIDNEY GRAFT THROMBOSIS, NEPHROTOXICITY and MORTALITY IN HEART TRANSPLANTATION Malignancies and Serious Infections Only physicians experienced in immunosuppressive therapy and management of transplant patients should prescribe Zortress. Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physician responsible for maintenance therapy should have complete information requisite for the follow-up of the patient [see Warnings and Precautions (5.1)]. Increased susceptibility to infection and the possible development of malignancies, such as lymphoma and skin cancer, may result from immunosuppression [see Warnings and Precautions (5.2, 5.3)]. Kidney Graft Thrombosis An increased risk of kidney arterial and venous thrombosis, resulting in graft loss, was...

What it is approved for

From the label in effect Sep 16, 2026.

Zortress is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult patients receiving a: Kidney Transplant : At low-moderate immunologic risk. Use in combination with basiliximab, cyclosporine (reduced doses) and corticosteroids ( 1.1) Liver Transplant : Administer no earlier than 30 days posttransplant. Use in combination with tacrolimus (reduced doses) and corticosteroids ( 1.2 , 5.5 ) Limitations of Use : Safety and efficacy have not been established in the following: Kidney transplant patients at high immunologic risk ( 1.3 ) Recipients of transplanted organs other than kidney or liver ( 1.3 , 5.7 ) Pediatric patients (less than 18 years) ( 1.3 ) 1.1 Prophylaxis of Organ Rejection in Kidney Transplantation Zortress is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunologic risk receiving a kidney transplant. Zortress is to be administered in combination with basiliximab induction and concurrently with reduced doses of cyclosporine and with corticosteroids. Therapeutic drug monitoring (TDM) of everolimus and cyclosporine is recommended for all patients receiving these products. 1.2 Prophylaxis of Organ Rejection in Liver Transplantation Zortress is indicated for the prophylaxis of allograft rejection in adult patients receiving a liver transplant. Zortress is to be administered no earlier than 30 days posttransplant concurrently in combination with reduced doses of tacrolimus and with corticosteroids. TDM of everolimus and tacrolimus is recommended for all patients receiving these products. 1.3 Limitations of Use The safety and efficacy of Zortress has not been established in the following populations: Kidney transplant patients at high immunologic risk. Recipients of transplanted...

Mechanism: Everolimus inhibits antigenic and interleukin (IL-2 and IL-15) stimulated activation and proliferation of T and B lymphocytes. In cells, everolimus binds to a cytoplasmic protein, the FK506 Binding Protein-12 (FKBP-12), to form an immunosuppressive complex (everolimus: FKBP-12) that binds to and inhibits the mammalian target of rapamycin (mTOR), a key regulatory kinase. In the presence of everolimus phosphorylation of p70 S6 ribosomal protein kinase (p70S6K), a substrate of mTOR, is inhibited. Consequently, phosphorylation of the ribosomal S6 protein and subsequent protein synthesis and cell...

Therapeutic areas: Oncology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • ZORTRESS · EVEROLIMUS 1MG · TABLET, ORAL · Prescription · TE AB
  • ZORTRESS · EVEROLIMUS 0.5MG · TABLET, ORAL · Prescription · TE AB
  • ZORTRESS · EVEROLIMUS 0.75MG · TABLET, ORAL · Prescription · TE AB
  • ZORTRESS · EVEROLIMUS 0.25MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Everolimus" as an intervention, any sponsor and status, largest first.

All 881 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • malignant neoplasm progression1,602
  • off label use1,422
  • diarrhoea1,307
  • drug ineffective1,035
  • death916
  • fatigue898
  • nausea816
  • product use in unapproved indication764
  • disease progression762
  • dyspnoea704
  • pyrexia682
  • pneumonia667

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20042
20065
200715
200833
200988
2010120
2011362
2012457
2013428
2014501
2015744
2016722
2017825
20181,244
20191,401
20201,934
20211,624
20221,780
20231,834
20241,800
20251,391
20261,186

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Zortress (Everolimus)

2024 spending

$1.4M

Beneficiaries

75

382 claims

Per beneficiary

$18,220

$22.89 per unit

View as table
YearSpending
2020$15,912,118
2021$9,443,154
2022$4,223,817
2023$1,994,088
2024$1,366,474

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,822 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.